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INTRODUCTION
18F-fluorodeoxyglucose (FDG) positron emission
tomography (PET)-based assessment of the myo-
cardium is useful in the evaluation of primary cardiac
tumors or cardiac metastasis, to examine the viabil-
ity following myocardial ischemia and for the detec-
tion of inflammatory myocardial sarcoid lesions.
However, because the cardiac FDG uptake shows
several different patterns in the fasting state, it is
often difficult to distinguish between normal or ab-
normal uptake. Therefore, it is recommended that
glucose loading should be performed to increase this
uptake prior to estimating the viability. In addition,
heparin loading is carried out to suppress the physi-
ological uptake of FDG in the myocardium before
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attempting the detection of inflammatory lesions,
such as sarcoidosis.
In Japan, the use of 18F-FDG PET was approved
by the national health insurance program for evalu-
ating cardiac sarcoidosis in 2012. It is therefore
speculated that the number of 18F-FDG PET exami-
nations for cardiac sarcoidosis will increase. How-
ever, the normal heart frequently shows physiologi-
cal uptake, and the physiological uptake is different
for each patient, and may even differ within individ-
ual patients during different examinations. There-
fore, it is often difficult to evaluate whether the up-
take is abnormal or not.
In the present study, we evaluated the physiologi-
cal cardiac accumulation of FDG under preparation
for tumor FDG-PET.
METHODS AND MATERIALS
This retrospective study was approved by the in-
stitutional review board of Tokushima University
Hospital.
A total of 207 consecutive outpatients who under-
went FDG-PET/CT for tumor imaging between
March 30, 2011 and May 13, 2011 at our hospital
were enrolled in this study. The suspected diseases
for which FDG PET/CT was used are shown in
Table 1. Nineteen patients were excluded for the
following reasons : 11 had cardiac disease (four
cases of angina, four of arrhythmia, one old myo-
cardial infarction, one congestive heart failure and
one had undergone pericardiectomy), seven patients
(four with esophageal cancer, three with lung can-
cer) had undergone radiation therapy during which
the heart was included in the irradiated field ; and
one patient had very poor imaging data due to obe-
sity. Therefore, we investigated a total of 188 pa-
tients (84 males and 104 females ; mean age, 64.1
years ; and age range, 27-90 years).
FDG PET/CT
All patients prepared for the examination by fast-
ing for at least six hours prior to tumor PET imag-
ing. After verification of their blood glucose level,
the patients were intravenously injected with 128-
290 MBq/kg of FDG. Patients were then examined
using a PET/CT scanner (Auiduo : Toshiba Medi-
cal Systems Corporation, Tochigi, Japan) one hour
after FDG injection. Image acquisition was per-
formed from the top of the head to the middle of
the thigh. The attenuation-corrected PET images,
non-attenuation-corrected PET images and CT im-
ages were reviewed, and the attenuation-corrected
PET and CT images were co-registered using a com-
mercial software program (Aquarius NET Viewer :
TeraRecon Inc, San Mateo, CA, USA).
Table 1. Underlying diseases of the patients evaluated by FDG PET/CT
n n
Breast cancer 53 Parotid gland lesion 4
Lung lesion 28 cancer (3)
cancer (21) other (1)
others (7) Malignant melanoma 3
Esophageal cancer 21 Maxillary cancer 3
Uterine cancer 16 Renal cancer 2
Laryngeal cancer 13 Gallbladder cancer 2
Gastric cancer 11 Colon cancer 2
Pharyngeal cancer 10 Bone tumor 2
Malignant lymphoma 6 Unknown primary cancer 2
Pancreatic lesion 6 Tongue cancer 2
cancer (2) Gingival cancer 1
others (4) Oral cancer 1
Thymic lesion 5 Brain tumor 1
cancer (2) Liver tumor 1
others (3) Thyroid cancer 1
Rectal cancer 4 Prostate cancer 1
Ovarian lesion 4 Pleural tumor 1
cancer (3) Cervical tumor 1
other (1)
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Analysis of the FDG PET images
The FDG uptake in the myocardium was classi-
fied into four patterns as described in two previous
reports (1, 2) : ‘none’, ‘diffuse’, ‘focal’ and ‘focal on
diffuse’ (Figure 1). The “none” pattern indicated no
uptake of FDG in the myocardium or less uptake
than was observed in the mediastinum. The “dif-
fuse” pattern indicated a diffuse and homogeneous
uptake of FDG in the left ventricle (LV) wall. The
pattern was only classified as “focal” when a focal
uptake was observed. The “focal on diffuse” pattern
indicated a focal uptake overlying the diffuse pattern.
However, if a focal nodular uptake was only seen
in the lateral wall of the LV, we did not classify the
pattern as a “focal” or “focal on diffuse” pattern, be-
cause normal papillary muscle often shows a focal
uptake in the lateral wall. When the “focal” or “focal
on diffuse” patterns were seen, we further classified
these focal FDG uptake patterns into three addi-
tional patterns when it was only observed in the
basal wall (Figure 2). These three patterns were the
‘ring’ pattern, ‘over half’ pattern and ‘spot’ pattern.
The ‘ring’ pattern was characterized by a diffuse ac-
cumulation of FDG in the basal wall, the ‘over half’
pattern showed more than 50% accumulation, and
the ‘spot’ pattern showed less than 50% accumula-
tion. Two or three board-certified radiologists, who
were blinded to all of the clinical information, per-
formed the visual analysis and classified the uptake
patterns.
Statistical analysis
The differences between the uptake patterns
based on the age, blood glucose level and weight
were evaluated using the Tukey test. A value of p
0.05 was considered to be statistically significant.
RESULTS
The frequencies of the myocardial FDG uptake
patterns were as follows : “none”, n=52 (27.7%) ;
“diffuse”, n=63 (33.5%) ; “focal on diffuse”, n=40
(21.3%) and “focal”, n=33 (17.6%) (Table 2). The
age, blood glucose level, weight and dose of FDG
did not differ significantly (p0.05) for each pattern
(Table 3). The “focal” and “focal on diffuse” pat-
terns were seen in 73 patients, and 65 of these pa-
tients exhibited focal uptake of FDG in the basal
Figure 2. The uptake pattern in the basal wall. a : ring, b : over half, c : spot
Figure 1. The left ventricular uptake pattern. a : none, b : dif-
fuse, c : focal, d : focal on diffuse
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wall only (‘ring’, n=29 ; ‘over half’, n=20 and ‘spot’,
n=16) (Table 4). Patients with a “focal on diffuse”
pattern did not have a ‘spot’ pattern, and only one
patient had a “focal” pattern with a ‘ring’ pattern.
Eight patients had focal uptake in other regions
(apex, n=4 ; lateral, n=3 and anterior, n=1).
DISCUSSION
The myocardium metabolizes fatty acids and glu-
cose as energy sources. With sufficiently extended
fasting, the myocardium shifts from a predominantly
glycolytic metabolism to a fatty acid metabolism (3).
In the clinical oncology setting, FDG PET is usually
performed on patients who have been fasting for
about six hours, so the fatty acid metabolism will be
predominant over the glucose metabolism. How-
ever, cardiac FDG uptake often shows several pat-
terns in the fasting state, and even in the same pa-
tient, the uptake can show different patterns at dif-
ferent times. There have been some previous reports
on the physiological cardiac FDG uptake (4-8). In
these reports, it was stated that the cardiac uptake
showed various patterns, but that parameters such
as the patient age, blood glucose level, weight and
dose of FDG were not related to the uptake patterns
in the myocardium. The myocardial metabolic rate
is relative to the serum free fatty acid levels, but it
does not depend only on the fasting period. In line
with these findings, it was found in our study that
the cardiac FDG uptake showed various patterns,
but no parameters had a significant effect on these
patterns.
Patients with cardiac disease, such as sarcoidosis
(1, 2, 9-12), pulmonary hypertension (13), hyper-
trophic cardiomyopathy (14-16), a tumor or damage
to the myocardium caused by radiotherapy (17-21)
show abnormally high accumulation of FDG. In ad-
dition, cardiac sarcoidosis shows focal uptake (1, 2).
We also investigated patients who showed focal
FDG uptake. Thirty-three patients (17.6%) exhibited
a “focal” pattern and 40 (21.3%) exhibited a “focal
on diffuse” pattern. A total of 73 patients (38.8%)
showed focal uptake. Thus, cardiac focal uptake was
frequently seen in patients without cardiac disease.
However, almost all of these patients (65/73, 89.0%)
accumulated FDG only in the basal wall, which
showed various patterns and degrees of focal uptake.
Therefore, the uptake in the basal wall did not al-
ways indicate an abnormal finding when an exami-
nation was undertaken in the fasting state. However,
patients without cardiac disease rarely show focal
uptake of FDG in other regions. In our study, only
eight of the 185 (4.3%) patients exhibited focal up-
take in another region. If we decided that the focal
uptake of FDG in the basal wall was normal, and
focal uptake in another region was abnormal, the
accuracy and specificity increased, but the sensitiv-
ity decreased, and we could not determine the true
level of abnormal uptake in the basal wall.
Heparin increases the serum free fatty acid lev-
els, reduces saccharometabolism and possibly mini-
mizes the background myocardial uptake of FDG.
Heparin also activates plasma lipoprotein lipase,
which separates fatty acids. It is difficult to evaluate
the cardiac uptake in the fasting state, so heparin
loading should be carried out before injecting FDG.
Table 2. Summary of the uptake patterns
Uptake pattern n %
None 52 27.7
Diffuse 63 33.5
Focal 33 17.6
Focal on diffuse 40 21.3
Total 188 100
Table 4. The area of focal uptake
Focal Focal ondiffuse Total
Basal
segment only
Ring 2 27 29
Over half 11 9 20
Spot 16 0 16
Other segments 4 4 8
Total 33 40 73
Table 3. The relationship between the uptake patterns and pa-
rameters
Uptake
pattern
None
n=52
Diffuse
n=63
Focal
n=33
Focal on
diffuse
n=40
Age 65.012.0 61.812.8 68.09.7 63.212.1
Blood
glucose
level
(mg/dl)
99.425.2 93.818.0 93.517.1 94.714.2
Weight
(kg) 55.3
11.7 57.110.8 57.08.4 56.59.4
Dose
(MBq) 201.8
41.3 210.433.7 208.029.1 209.935.6
None of the differences were statistically significant (p0.05)
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When heparin loading is performed in patients with-
out cardiac disease, the cardiac FDG uptake showed
either the “none” pattern or the “diffuse” pattern,
so we can easily evaluate the cardiac uptake. It is
useful to use cardiac MRI or blood-flow scintigra-
phy in combination with this approach.
A major limitation of our study is that we labeled
some patients as having no cardiac disease on the
basis of only the clinical symptoms and anamnesis,
so it could not be definitely confirmed that all of the
enrolled patients were free from cardiac disease.
CONCLUSIONS
The physiological myocardial FDG uptake fol-
lowed several patterns and frequently involved a
focal uptake. Therefore, a focal uptake was often
seen in patients with some cardiac diseases. How-
ever, this uptake did not necessarily indicate ab-
normal findings when the FDG accumulation only
occurred in the basal wall. We should therefore be
aware of the physiological uptake pattern when PET
examinations are performed on patients in a fast-
ing state.
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